Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?

Great question with limited data to give a "correct answer." I have seen CNS response to checkpoint inhibitors, but I do not expect CNS response from it. In my practice, if I saw truly isolated CNS failure with good systemic control, I would continue checkpoint inhbibitory therapy as long as it was ...